Natsar Pharmaceuticals
Ellicott City, US · Delaware corporation
Find your way into Natsar Pharmaceuticals
53 people in our graph share verified history with the Natsar Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.
Tea Eleziunlockedknows Venu Raman · together at Utrecht University (overlapped)
×11knows the team · via Utrecht University
Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.
Founders & leadership
VR
Venu RamanFounder and CSOVenu Raman is a cancer biologist and professor at Johns Hopkins University who has conducted research on developmental cancer mechanisms and gene dysregulation. He founded Natsar Pharmaceuticals to develop RK-33, a small molecule inhibitor targeting the DDX3 RNA helicase for cancer and viral treatment applications.
Reported raises · per SEC filings
Form D private placements$4.2M disclosed across 1 round · 2026
▶$4.2MraisedMay 2026 · 15 investors · PharmaceuticalsRule 506(b)
▶$4.2MraisedMay 2026 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Venu RamanExecutive Officer, Director
- Amount sold
- $4.2M
- Minimum investment
- $1
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Adarx8 shared keywordsADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes. It focuses on treatments for a range of diseases with unmet medical needs.
Day One Biopharmaceuticals8 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Aurinia Pharmaceuticals8 shared keywordsAurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs. The company's marketed product LUPKYNIS treats active lupus nephritis, and it is also developing aritinercept for broader autoimmune indications.
Samsara7 shared keywordsSamsara Therapeutics develops small-molecule therapeutics that activate autophagy to slow the progression of age-related neurodegenerative diseases such as ALS, Parkinson's, and Charcot-Marie-Tooth disease. It runs an in-house phenotypic screening platform using patient-derived iPSCs to identify and validate autophagy activators for drug discovery.
Ars Pharma7 shared keywordsARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies. It serves patients with allergies and their caregivers.
Companies competing with Natsar Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Biomedical Data Manifest: A lightweight data documentation mapping to increase transparency for AI/ML | Scientific Datanature.com · Feb 2026Frequently asked questions
- What does Natsar Pharmaceuticals do?
- Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.
- Who founded Natsar Pharmaceuticals?
- Natsar Pharmaceuticals was founded by Venu Raman.
- How much funding has Natsar Pharmaceuticals raised?
- Natsar Pharmaceuticals has disclosed $4.2M raised across 1 round.
- Where is Natsar Pharmaceuticals headquartered?
- Natsar Pharmaceuticals is headquartered in Ellicott City, US.